Programs

EP4R antagonist for immuno-oncology

mGluR4/7/8 positive allosteric modulator for Parkinson’s disease

NPFFR small molecule antagonist to combat the opioid crisis

PAR2 negative allosteric modulator for rare inflammatory diseases

First-in-class anti-GPCR antibody for immuno-oncology

MC4R pharmacochaperone for the treatment of early onset obesity

Best-in-class treatment for immuno-oncology

Orphan GPCRs for Central Nervous System (CNS) disease area

New GPCRs target identification and validation

First-in-class CXCR4 agonist to control auto-immune diseases

Sema3A fusion protein for immuno-oncology

First-in-class mGluR3 PAM for Parkinson’s disease

Transmembrane peptide-based platform

EXITED - acquired by Lundbeck 2018

EXITED - out-licensed to Merck 2017